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Abstract
A continuously mixed series of microbial communities inhabits
various points of the respiratory tract, with community composition
determined by distance from colonization sources, colonization
rates, and extinction rates. Ecology and evolution theory developed in
the context of biogeography is relevant to clinical microbiology
and could reframe the interpretation of recent studies comparing
communities from lung explant samples, sputum samples, and
oropharyngeal swabs. We propose an island biogeography model
of the microbial communities inhabiting different niches in human
airways. Island biogeography as applied to communities separated
by time and space is a useful parallel for exploring microbial
colonization of healthy and diseased lungs, with the potential to inform
ourunderstandingofmicrobial communitydynamics and the relevance
of microbes detected in different sample types. In this perspective,
we focus on the intermixedmicrobial communities inhabiting different
regions of the airways of patients with cystic ﬁbrosis.
When we try to pick out anything by itself,
we ﬁnd it hitched to everything else in
the Universe.
—John Muir,My First Summer in the Sierra
Individual humans, and their organs and
tissues, can be considered islands. Like
the islands of the Galapagos, humans
constitute spatially structured environments
that offer microbes abundant ecological
opportunity (Figure 1). The Human
Microbiome Project (http://www.hmpdacc.
org/) has shown that different organs
and systems within the human body are
inhabited by different species assemblages
(1). Just as the islands of an archipelago
are exposed to a reservoir of potential
emigrants from the mainland, individual
human organ systems are exposed to
potential migrants from the surrounding
milieu. Irrespective of speciﬁc habitat
details, community assembly and stability
are driven by dispersal rates and priority
effects, with the order and timing of arrival
inﬂuencing the fate of particular species (2, 3).
The diversity of species inhabiting the
islands of an archipelago depends on how
close each island is to a mainland (from
which colonizing species are derived) and
the rate that species go extinct (Figure 2).
The theory of island biogeography, born
in the 1960s (4), includes islands of
many different sorts: islands as mountain
tops, lakes, trees, and in fact any set of
niches separated by time, space, or an
environmental barrier. Although studies
of island biogeography initially focused
on ecology, there has long been awareness
that patterns of species diversity cannot be
fully understood outside the evolutionary
processes that fuel diversiﬁcation (5).
Indeed, incorporation of evolutionary
thinking into ecology has underpinned
advances in understanding adaptive
radiation, speciation, and opportunities
for ecosystem restoration.
In extreme cases, for example after
a forest ﬁre, the process of community
assembly is given special prominence (6).
However, the same processes that lead
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to reestablishment of a forest on barren
land may also govern the formation of
host-associated microbial communities.
Community assembly has important
implications for health and disease (2, 3, 7).
For example, the capacity for a pathogen
to establish itself in a given niche is likely
to depend on the presence (or absence)
of competing microbes (8–12), the timing
of arrival, and the history of colonization
events. Establishment will also be affected
by host factors, including the immune
system, the availability and quality of
nutrients (their spatial and temporal
distribution), and the physical structure
and properties of tissues and surfaces.
Island Culture: Distinct
Communities Intermingle in
the Oropharynx–Airway–Lung
Ecosystem
As islands that provide ecological
opportunity to microbes, the unique
environment of the lung in diseases such
as cystic ﬁbrosis (CF), chronic obstructive
pulmonary disease (COPD), and other
inﬂammatory respiratory conditions are
of special interest. Microbes immigrating
to the lung come from various sources,
including air, water, and food, but also
from the oral cavity and other nearby
islands, such as the sinuses and even the
gastrointestinal tract. In the model proposed
here, the oral cavity might be considered
as the mainland, or the largest, most diverse
proximal island, and various niches in
the respiratory tract as islands (Figure 2).
Like modern ecologists who ﬁnd exceptions
to the original island biogeography theory
Figure 1. Parallels between island biogeography and polymicrobial lung colonization. (Left) In island biogeography theory, the mainland is the greatest
source of species diversity, with individual island species composition depending on the distance from the mainland. (Middle) Human airway microbial
colonization is likely to display a similar dependence on the distance from the mainland (largely the oral cavity, shown in yellow, which is the richest
and most diverse source of microbes with proximity to the lung). (Right) Other people, along with the air, water, and other environments, are also important
sources of microbes, which can immigrate to the islands in the human airways and influence the polymicrobial community.
Figure 2. Classic island biogeography. The richness of species depends on the colonization rate
(left y-axis) and the extinction rate (right y-axis). Migration through the trachea offers colonization
opportunity to microbes from multiple sources, and impaired mucociliary clearance decreases the
extinction rate. Gray circle 1 represents a small distant island (i.e., the lung) with few species, whereas
gray circle 2 identifies the mainland or a large proximal island with high species diversity, such as
the oral cavity. Diversity is composed of both the number of species and their distribution, or
evenness, and can be indicated by different measures of species richness and frequency. The
number of species, or species richness, is an indicator of diversity. The term diversity is used
throughout this perspective as informed by the species richness, which can be predicted in the
island biogeography model. Adapted by permission from Reference 4.
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of the 1960s, it is necessary to acknowledge
the inﬂuence of factors beyond the size
and remoteness of island reservoirs on
community diversity (as indicated by
species richness) (13). In patients with
CF, the immune system, interspecies
interactions, and antibiotic pressure exert
profound additional inﬂuences on
microbial community structure.
Microbes traditionally inhabiting
the oral cavity that are also capable of
colonizing the lower airways are likely
to be an important source of attack
community microbes in lungs, as presented
in the climax–attack model (14). The
climax–attack model postulates that
there are two major microbial or viral
communities inhabiting the CF lung: a
well-adapted, persistent climax community
and an attack community composed of
more virulent and transient microbes
and viruses. Although the oral cavity
hosts a large diversity of microbes, the
most abundant species found deep in
explanted lung samples from patients with
end-stage disease are usually from a small
group of known CF pathogens, including
Pseudomonas aeruginosa, Stenotrophomonas
maltophilia, Staphylococcus aureus, and
Burkholderia cenocepacia (15). Furthermore,
well-studied clinical isolates of P. aeruginosa
often harbor a subset of common mutations
that reveal their adaptation to the CF
lung environment (16–18). Recent evidence
suggests a similar trend in Rothia mucilaginosa,
a bacterium traditionally considered to be
part of the oral microbial community (19).
Oral microbes that do not normally
inhabit the lungs are likely to signiﬁcantly
impact lung pathophysiology through the
interconnected oropharynx–airway–lung
ecosystem. Even if those oral microbes
remain in their endemic location (the oral
cavity), they may still impact populations
in the lung by producing metabolites that
passively travel to the lungs (20–22) or by
stimulating systemic host responses that
could directly impact the deep airway
microbial community. Additionally, given
the potential for these oral microbes to
emigrate to the lungs across the continuum
of the respiratory system, these same
microbes may be important competitors
and thus regulators of lung-invading
microbes. Bacteriophage and other agents
of gene exchange may also transfer
DNA-encoded traits (e.g., antibiotic
resistance) (23, 24). Microbes within the
oral cavity, and their migration from that
source, are therefore likely to be important
contributors to lung disease. It is critical
that all such sources are identiﬁed and
studied so that their connection with
the CF lung can be understood.
Given the potential for mainlandmicrobes
to directly and indirectly affect lung
communities, we argue that to understand the
evolution of polymicrobial lung communities,
and their related pathophysiologies, ecological
dynamics must be acknowledged both within
resident lung microbial communities and in
neighboring niches.
Some have argued that oral
commensals detected in sputum samples
used to interrogate lung microbial
communities represent contamination
from the oral cavity (15, 25, 26). However,
the degree to which oral microbes may
emigrate and persist in lower airways is
likely to vary from one patient to the
next, depending on the presence of speciﬁc
microbes as well as a variety of other
environmental and host factors. Thus,
tracking all airway microbes is important
because oral microbes need not frequently
form resident communities in the lower
airways to profoundly inﬂuence polymicrobial
community physiology.
A Bridge to the Lung:
Migration across the Trachea
The physical continuum of the trachea
connects the oral cavity and the lungs.
Indeed, lung samples from healthy humans
are not sterile, and they occasionally contain
microbes traditionally associated with the
oral cavity (27–30). The density of bacteria
in the oral cavity is orders of magnitude
greater than the healthy lung (27). The
composition and even the existence of
microbial communities in healthy human
lungs is an active area of research. Whether
the upper and lower respiratory tracts of
healthy people contain “tourists,” which
are quickly expelled, or whether there
exist resident microbial communities is
an important question (27, 29, 31–33).
Either way, differences in commensal and
pathogenic microbial load in the airways
of healthy humans and those affected by
various respiratory conditions are likely
to be affected by the rate at which new
types enter the system and the rate at which
they fail to colonize or go extinct.
Healthy and diseased lungs are equally
accessible to microbial migrants—they
both contain a bridge across the trachea,
and, signiﬁcantly, migration may not
always result in persistent colonization.
Healthy lungs have coordinated
mucociliary clearance (34) that forces
microbes out, and this limits the time
for adaptation and establishment. This
means the extinction rates of microbes
that reach the lower airways are much
higher in healthy lungs; impaired
mucociliary clearance will reduce extinction
rates and lead to larger numbers of species
colonizing the lower airways (Figure 2).
Emigration of oral microbes to the lower
airways due to aspiration is important in
a number of respiratory conditions, in
which a large fraction of infections are
believed to have oral microbial etiology
(35–39). Respiratory conditions associated
with decreased extinction of microbes
that reach the lower airways include
smoking (31), vaccination and probiotics
(40, 41), respiratory virus infection (42–44),
pneumonia (36), HIV (45, 46), COPD
(30, 47–49), and CF (50). In addition,
improvements in oral hygiene practices in
hospitals have been shown to prevent
pneumonia (51). In newly transplanted
lungs of patients with CF, strains of bacteria
found in the sinuses are later found
in the newly transplanted lungs, again
suggesting that microbes in the sinuses have
a route to the lower respiratory tract (52).
In CF, the epithelia lining the airways
are covered by abnormally dense mucus,
trapping the cilia and rendering them
nonfunctional (53). In addition, lung-speciﬁc
immune responses are impaired in CF,
including dysfunctional alveolar macrophages
and autophagy (54–56). Together, these
defects allow the commonly observed
opportunists, such as P. aeruginosa and
B. cenocepacia, to persist in CF airways.
Most patients harbor unique and persistent
microbial communities, suggesting differences
from patient to patient in exposure
to microbial immigrants, or selective
pressures, or both. Although the well-
known opportunistic pathogens are clearly
important, they do not exist in isolation;
interactions with other community
members have important implications
(11, 57–59). Indeed, there are increasing
examples of infections driven by an altered
polymicrobial community, rather than
a single pathogen, and these will likely
inﬂuence how clinicians diagnose and treat
infections (59, 60). Pneumonia, COPD,
CF, chronic sinusitis, periodontitis, and
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otitis media are examples of infections in
which a commensal from one human site
can emigrate to become a pathogen in
another context (36, 51, 61–66). Like
drifting seeds from a proximal island,
exposure and survival rates of microbes
from nearby habitats stand to profoundly
inﬂuence microbial community
composition and interactions.
Spoiled Sputum?
As sampling of the lungs of a living human
generally requires passage through the
oral cavity, the question of how frequently
and how deeply oral microbes penetrate into
the lower airways is unresolved. Invasive
lower airway sampling methods such as
bronchoalveolar lavage (BAL) enable careful
sampling of a speciﬁc region of the lung with
reduced potential for contamination, but
these methods cannot be performed on
a regular basis because of negative impacts
on patients. Sputum and BAL samples are
also limited in the extent to which they
provide insight into spatial distribution of
microbes within the airways. Currently,
when typical CF pathogens are not found in
CF sputum cultures, clinical microbiology
labs report them as culture negative (67),
essentially disregarding oral microbes as
contaminants without clinical relevance.
Given the interconnected topography of
the oral cavity and the airways, it would not
be surprising to learn that some microbial
groups are found in both the oral and
lung environments. Direct evidence that
organisms considered oral contaminants
are present in the large airway exists from
early culture studies based on transtracheal
aspirates, where mixing with oral microbiota
is avoided (68). In addition, next-generation
sequencing has often detected surprisingly
high relative abundances of species such
as Streptococcus spp., R. mucilaginosa, or
Gemella spp. in large volumes of purulent
sputum (milliliters to tens of milliliters)
(11, 19, 69). Overall, although there are
limitations associated with sputum samples,
the fact that they can be obtained by
noninvasive means, and that they show
patterns of diversity similar to lower and
upper airways (8, 15, 16, 34), suggest it is
sensible to obtain as much information
from sputum samples as possible.
To directly assess lung microbial
communities, multiple studies have
examined the microbes present in explant
lung samples. These samples carry their
own caveat—they are most often obtained
from patients with end-stage disease and
have been shown to contain signiﬁcant
regional differences in community
composition and severely reduced diversity
(30, 70, 71). In an attempt to reconcile
the different caveats of sputum and explant
lung samples in CF, a study by Goddard
and colleagues in 2012 compared throat,
sputum, and explant lung samples (average
of all lobar bronchi) from the same patients
with CF, close to the time of transplant
surgery (15). This study concluded that
next-generation sequencing of DNA in
sputum samples inaccurately represents
airway microbial communities and that
oral microbes detected by this method
should be regarded as contaminants.
We present a complementary analysis
of Goddard and colleagues’ 2012 data.
Whereas Goddard and colleagues present
the relative abundance of taxa as bar
plots, we took the relative abundance data
from their supplementary material and
visualize an unsupervised random forest
in a multidimensional scaling plot. The
bar plots of Goddard and colleagues and
our analysis both show that the overall
microbial community composition of
sputum samples closely resembles that
of the explanted lung samples in half of
the six samples tested (72) (Figure 3). In
the other three patients, additional microbes
traditionally considered oral commensals
were found in sputum samples and were
not found in the explanted lung samples.
However, for all samples, the dominant
microbe found in sputum was the same
as the dominant microbe found in the
explant lung samples. The lack of additional
commensal microbes in three of the
sputum samples may reﬂect antibiotic
treatment and disease state rather than
a lack of oral contamination. We therefore
favor the interpretation that microbes
considered as contaminants might be
important components of CF lung ecology.
We list some issues that warrant
consideration.
First, the careful study of explanted
lungs presented by Goddard and colleagues
provides valuable information about the
end-stage disease–associated microbial
community DNA found in CF explanted
lungs. However, end-stage disease
communities are not representative of
microbial community composition and
activity during earlier stages. One of the
most consistent signatures of CF airway
microbial community evolution from
longitudinal sputum sampling is the
increase in antibiotic-resistant pathogen
load as disease state becomes more severe
(15, 50, 73–75). Furthermore, by the time
a lung is surgically removed, many of
the airways have undergone bronchiectasis
and become clogged, no longer exchanging
air with upper airways. Substantially
reduced microbial diversity is expected
Figure 3. Multidimensional scaling of an unsupervised Random Forest comparing the relative
abundance of taxa derived from 16S sequencing of lung explant samples (red) with sputum samples
(blue) and oropharyngeal swabs (green) from six patients with cystic fibrosis (CF) (15). Shared
community composition leads to clustering of sputum and lung samples in most cases, whereas
some sputum and throat samples cluster together. Data from Reference 15; analysis conducted in
R with the package Random Forest (72).
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in explant samples and is very different
from the microbial community composition
in the airways of younger patients with CF
with less severe disease (76). Community
interactions involving the more diverse
repertoire of microbes found in younger,
earlier-stage patients are integral to the
evolution of the community toward a less
diverse, more antibiotic-resistant state found
at the end stage of respiratory diseases
and should be studied in greater detail.
Second, sputum may come into contact
with oral microbes independent of the
collection of the sputum sample. Sputum
may accumulate in areas between the throat
and the lobar bronchi in some patients,
and oral microbes may inhabit these sites.
Half of the six sputum samples reported
by Goddard and colleagues had a low
abundance of oral microbes. This dearth of
microbes may have been due to long-term
antibiotic use and acute antibiotic treatment
after an exacerbation (70, 73, 75, 77). The
other three sputum samples did contain
a greater abundance of oral microbiota
compared with the explant samples,
matching microbes identiﬁed in throat
swabs. The presence of oral microbes could
be signiﬁcant to disease progression.
Third, the authors note that they made
no attempt to separate intact microbes
from the surrounding material, neither in
the sputum samples nor in the explanted
lung samples. This is relevant because
P. aeruginosa is known to rely on large
amounts of extracellular DNA from
coordinated cell death for bioﬁlm formation
(78). This DNA could accumulate over time
and exaggerate the apparent abundance of
Pseudomonas relative to other microbes,
especially in a context like the lower airways
of patients with severe disease, where little
disruption of the microbial communities
would take place (79). In many explanted
lungs, the authors did in fact detect
some microbes typically considered oral
commensals (such as Streptococcus spp.)
but at much lower abundances than in
sputum. If the relative abundance of
Pseudomonas was exaggerated by the
sampling method, then the low but nonzero
relative abundances of oral microbes could
be much higher than originally considered
by the authors. However, it is important
to note that high abundance does not
equal ecosystem importance, as some oral
microbes may be able to inﬂuence lung
microbial communities even at very low
abundances (64, 65).
Moving Forward:
Understanding Colonization
and Migration Events in
Respiratory Infections
Further study is required to understand
the dynamics of airway microbial
communities that are relevant to disease.
Human airways are exposed to microbes
from many sources. Although the persistent
microbial community of the adjacent
oral cavity is likely to be a dominant
source, additional sources include nearby
humans (other archipelagos, in Figure 1),
animals, the home, water, food, and
other environmental reservoirs capable
of creating airborne particulate matter.
By analogy to the island biogeography
example, the oral cavity can be thought
of as a mainland species reservoir; the
communities that become established in
these locations can have a profound effect
on the prospective colonizers of more
remote islands further down the chain.
Understanding where reservoirs of relevant
microbes exist could help avoid or delay
colonization, inform therapeutic strategies,
and potentially improve clinical outcomes.
Fortunately, modern omics proﬁling—
next generation sequencing, proteomic,
and metabolomics measurements—now
allows the identities and activities of
both chronic microbial communities
and drifting microbial seeds to be
identiﬁed with unprecedented depth
and breadth. New technologies and
decreasing costs allow for measurement
of taxonomic identities, genome content,
and transcriptomic, proteomic, and
metabolomic activity of microbes in
sputum samples. Insights into how
movement and changes in activity of
lung and oral microbes may precipitate
exacerbations and other pathophysiological
changes should be possible. The next major
challenge is designing careful studies so that
the large amounts of new data can give
a clear picture of the spatial and temporal
dynamics of these communities and lead to
understanding of how these dynamics
impact clinical outcomes. The biological
question should dictate the most appropriate
sampling approach. Standardization of
sample collection and processing protocols is
essential to producing data that can be
compared, regardless of sample type.
The island biogeography analogy can
be used to develop criteria for better
understanding the relationships among
traditionally “oral” and traditionally “CF
pathogen” microbes. There may be cases
where sputum samples are contaminated,
and there may also be cases where “oral”
microbes become established deeper in
the CF lung. For example, Rothia
mucilaginosa, a microbe traditionally
found in the oral cavity, has been
consistently found in high numbers in CF
sputum, and in explant samples in some
cases (19). Perhaps these cases could
be distinguished by deep longitudinal
sampling. Evidence of oral microbes
becoming established in the lung could
include (1) persistence over time, (2)
stable abundance, and (3) genetic
adaptation. These three lines of evidence
are all predicted by island biogeography
and evolutionary theory. Additional
methods may also decipher the
contributions of all airway microbes to
the community dynamics. So far, little
change in measurable density or
composition of microbiota has been
observed preceding CF disease ﬂares
known as pulmonary exacerbations
(73, 77, 80). However, breath gas analysis
and metabolite analysis of sputum
samples may capture a valuable snapshot
of metabolic activity that reﬂects the
physiology of both the human host and
microbes (20, 22, 81). Transcriptomic and
proteomic analyses may also give deeper
insight into not only the taxonomy of
microbes present but also their activities.
Finally, new imaging techniques may
eventually allow a noninvasive window
into the spatial distribution of sputum
accumulation within the airways of
patients (82).
In conclusion, understanding
polymicrobial community dynamics
in health and disease is a compelling
challenge in 21st century medicine, with
consequences for infection diagnosis and
treatment. Applying island biogeography
theory to microbial communities
inhabiting niches in the human airways
informs our interpretation of the role of
microbes found in different human sample
types. When microbes that are typical of
the oral cavity are found in sputum or
BAL samples from patients with CF, they
should be considered potential immigrants,
rather than contaminants. Regardless of
whether microbial seeds originate from
the mainland oral cavity or an adjacent island
in the airways, they have the capacity to alter
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the dynamics of the polymicrobial community
that impacts the patient’s quality of life. n
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